In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BridgeBio raises $299.2mm in late-stage round

Executive Summary

BridgeBio Pharma raised $299.2mm through a late-stage venture round co-led by existing investors KKR and Viking Global Investors. Returning backers Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital also participated, along with first-time buyers Sequoia Capital and an undisclosed blue-chip long-term investor. BridgeBio is developing treatments for rare genetic diseases and will use the proceeds to support activities related to its pipeline of over 15 candidates in the areas of dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies